Adaptimmune Therapeutics plc ADAP
Nov 21, 2025, 9:30 AM EST
52-week range unavailable
- YTD
- -91.00%
- 1 year
- -93.42%
- Market cap
- 148.11M
- Revenue (ttm)
- 141.46M
- Profit margin
- -51.25%
- Shares out
- 255.88M
- Forward P/E
- -1.52
- YTD return
- -91.00%
- 1-year return
- -93.42%
- Volume
- 1.68M
- Open
- 0.0425
- Previous close
- 0.0485
- Day's range
- 0.0425 – 0.0599
- Beta
- 2.25
- Price target
- 2.27 (+4573.5%)
Key statistics
- Enterprise value
- 739.74M
- PEG ratio
- 0.00
- Price / sales
- 1.05
- Price / book
- 3.33
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 2399.60%
- Free cash flow
- -7.95M
- Total cash
- 214.79M
- Total debt
- 47.35M
- Return on equity
- -65.04%
- Short % of float
- 3.14%
- 50-day average
- 0.71418
- 200-day average
- 1.03
Analyst view
- Target (low)
- 1.00
- Target (mean)
- 2.27
- Target (high)
- 3.50
- Strong buy2
- Buy4
- Hold2
- Sell0
- Strong sell1
Next earnings
Consensus EPS estimate -0.154.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 13, 2024 | Sep 1, 2024 | -0.17 | -0.07 | +0.10 | +58.82% |
| Aug 12, 2024 | Jun 1, 2024 | 0.00 | 0.27 | — | — |
| May 15, 2024 | Mar 1, 2024 | -0.16 | -0.18 | -0.02 | -12.50% |
| Mar 6, 2024 | Dec 1, 2023 | -0.12 | -0.24 | -0.12 | -100.00% |
| Nov 8, 2023 | Sep 1, 2023 | -0.20 | -0.20 | 0.00 | 0.00% |
| Aug 9, 2023 | Jun 1, 2023 | -0.17 | -0.21 | -0.04 | -23.53% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 27, 2024 | Mizuho | main | Outperform | Outperform |
| Nov 19, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Nov 15, 2024 | Guggenheim | main | Buy | Buy |
| Nov 14, 2024 | HC Wainwright & Co. | main | Buy | Buy |
| Aug 13, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Aug 5, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
About Adaptimmune Therapeutics plc
Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops SPEARHEAD-1 that is in phase II clinical trials with ADP-A2M4 for synovial sarcoma; SURPASS-3 that is in phase II clinical trial with ADP-A2M4CD8 for people with platinum resistant ovarian cancer; and SURPASS that is in phase I clinical trials in patients with head and neck, and urothelial cancers. The company has strategic collaboration and license agreement with Genentech, Inc. and F. Hoffman-La Roche Ltd to develop personalized allogeneic and allogeneic T-cell therapies; research, collaboration, and license agreement with Universal Cells, Inc.; third-party collaborations with Noile-Immune and Alpine Immune Sciences; and strategic alliance agreement with the MD Anderson Cancer Center. Adaptimmune Therapeutics plc was founded in 2008 and is headquartered in Abingdon, the United Kingdom.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United Kingdom
- Website
- adaptimmune.com
News
Merck Announces New Agreement with ADAP Crisis Task Force to Improve Access and Care for People Living with HIV 
Adaptimmune Announces Changes to Board and Executive Leadership Team 
12 Health Care Stocks Moving In Monday's After-Market Session 
12 Health Care Stocks Moving In Wednesday's Intraday Session 
AHF: 80 Organizations Denounce Gilead on Price Hikes Gutting ADAP 
Why Crown Holdings Shares Are Trading Higher By Around 9%; Here Are 20 Stocks Moving Premarket 
12 Health Care Stocks Moving In Monday's Intraday Session 
Dow Jumps Over 200 Points; Cleveland-Cliffs Shares Jump After Q3 Results 
Adaptimmune Announces Delisting from Nasdaq - 12 Health Care Stocks Moving In Thursday's Pre-Market Session
Your note
Sign in to keep a note on ADAP — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BERTRAND WILLIAM C JR | Chief Operating Officer | Sale | Jan 16, 2024 | 20,201 |
| LUNGER JOHN | Officer | Sale | Jan 16, 2024 | 19,015 |
| MENZEL GARRY E | Director | Sale | Jul 9, 2023 | 75,056 |
| NORRY ELLIOT | Officer | Sale | Jan 16, 2024 | 19,257 |
| PICCINA CINTIA | Officer | Sale | Jun 17, 2024 | 38,293 |
| RAWCLIFFE ADRIAN | Chief Executive Officer | Sale | Jan 16, 2024 | 44,848 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Matrix Capital Management | 14.73% | 37,681,515 | 21.81M | Sep 29, 2024 |
| EcoR1 Capital, LLC | 10.71% | 27,404,070 | 15.86M | Sep 29, 2024 |
| NEA Management Company, LLC | 6.67% | 17,079,778 | 9.89M | Sep 29, 2024 |
| Baillie Gifford and Company | 6.56% | 16,775,860 | 9.71M | Sep 29, 2024 |
| Long Focus Capital Management, LLC | 5.20% | 13,299,890 | 7.70M | Sep 29, 2024 |
| Pfm Health Sciences, Lp | 3.91% | 10,000,787 | 5.79M | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| SPDR Portfolio Developed World ex-US ETF | 0.10% | 246,307 | 142.56K | Sep 29, 2024 |
| SPDR (R) Idx Shares-SPDR (R) S&P (R) International Small Cap ETF | 0.06% | 148,385 | 85.89K | Sep 29, 2024 |
| Fidelity Enhanced Small Cap ETF | 0.06% | 161,545 | 93.50K | Oct 30, 2024 |
| Fidelity NASDAQ Composite Index Fund | 0.05% | 139,801 | 80.92K | Oct 30, 2024 |
| Trust for Professional Managers-ActivePassive International Equity ETF | 0.02% | 44,364 | 25.68K | Aug 30, 2024 |
| Northern Small Cap Core Fund | 0.01% | 16,891 | 9.78K | Sep 29, 2024 |